查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2009157

體外大腸直腸癌篩檢市場規模、佔有率、趨勢和預測：按產品類型、影像方法、最終用戶和地區分類，2026-2034年

In-vitro Colorectal Cancer Screening Tests Market Size, Share, Trends and Forecast by Product, Imaging Type, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2025年全球體外大腸直腸癌篩檢市場規模為11.013億美元。預計到2034年，該市場規模將達到17.097億美元，2026年至2034年的複合年成長率（CAGR）為4.76%。北美目前在該市場主導，預計2025年市佔率將達39.8%。推動該市場成長的因素包括全球大腸直腸癌發病率上升、早期檢測意識增強以及非侵入性診斷方法的日益普及。檢測準確性和易用性的技術進步進一步促進了市場成長。此外，政府支持、人口老化以及預防醫學的興起也促進了市場需求的成長。與傳統篩檢方法相比，體外檢測的便利性、經濟性和高效性也是體外大腸直腸癌篩檢市場佔有率不斷擴大的重要原因。

體外大腸直腸癌篩檢市場的主要促進因素之一是對非侵入性居家診斷解決方案日益成長的需求。傳統的篩檢方法，例如大腸鏡檢查，通常被認為不舒服、昂貴且不方便，導致許多人放棄篩檢。而糞便免疫化學檢查(FIT) 和糞便 DNA 檢測等體外檢測方法則提供了更簡單、更無痛的替代方案，無需醫療人員協助即可在家中進行。這種便利性顯著提高了患者的依從性，尤其是在老年人和高風險族群中，並擴大了篩檢的覆蓋範圍。隨著醫療保健系統將預防醫學置於優先地位，向非侵入性檢測的轉變將繼續推動體外大腸癌篩檢市場的成長。

在美國，體外大腸癌篩檢市場正穩定成長，這主要得益於完善的醫療保健基礎設施、人們對早期癌症檢測意識的提高以及對非侵入性居家診斷方式的青睞。到2023年，50至75歲的美國成年人中，將有72.6%接受最新的大腸直腸癌篩檢，而居家檢測在這一目標的實現中發揮了重要作用。患者越來越傾向於選擇糞便免疫化學檢查和糞便DNA檢測等居家檢測方法，而非大腸鏡檢查等侵入性檢查。包括血液篩檢和生物標記創新在內的技術進步，進一步提高了檢測的準確性，並擴大了檢測選擇範圍。支持性政策、保險覆蓋以及對預防醫學的重視，持續推動美國醫療產業的市場需求。

體外診斷大腸直腸癌篩檢市場的發展趨勢：

全球大腸直腸癌發生率不斷上升

體外大腸篩檢篩檢的主要市場趨勢之一是全球大腸直腸癌發生率的上升。 2020年，全球報告了約193萬例新增大腸癌病例和93萬例相關死亡病例。預計到2040年，這些數字將成長超過60%。大腸直腸癌是最常見的惡性腫瘤之一，也是癌症死亡的主要原因。導致其發病率上升的因素包括久坐的生活方式、不健康的飲食、肥胖率的上升以及人口老化。早期發現能夠顯著改善預後，因此對便利性、非侵入性的篩檢檢測的需求日益成長。糞便免疫化學檢查和糞便DNA檢測等體外診斷檢測是經濟高效、擴充性的解決方案，是早期發現的理想選擇。各國政府和衛生組織正在擴大實施全國性篩檢項目，以降低死亡率。隨著全球對早期診斷重要性的認知不斷提高，體外診斷檢測在醫療保健系統中的應用也不斷擴展。

篩檢方法的技術進步與創新

持續的技術進步顯著提高了大腸直腸癌體外篩檢的敏感度、特異性和便利性。與傳統方法相比，新一代糞便免疫化學檢查（FIT）、DNA糞便檢驗和基於生物標記的診斷方法能夠提供更準確、更穩定的結果。自動化、人工智慧和數位病理學在診斷流程中的應用縮短了檢測時間，減少了人為誤差，並提高了診斷處理能力。這些改進使篩檢對患者和醫療服務提供者都更具吸引力，從而提高了篩檢參與率。此外，便捷的家用檢測套組的開發使得篩檢變得輕鬆私密，對於那些不願接受大腸鏡檢查等侵入性檢查的人來說，這無疑是一個極具吸引力的選擇。在診斷領域競爭日益激烈的背景下，各公司正大力投資研發，以開發創新、經濟且擴充性的體外檢測方法，這將推動市場的長期擴張，並塑造癌症早期檢測的策略。

人們越來越偏好非侵入性和居家篩檢。

體外診斷大腸直腸癌篩檢市場的主要促進因素之一是患者對非侵入性、居家診斷工具日益成長的需求。雖然大腸鏡檢查等傳統方法非常有效，但通常被認為不舒服、昂貴且不方便。相較之下，FIT 和多標靶糞便 DNA 檢測等體外檢測可以在家中悄悄進行，無需腸道準備、鎮靜或住院。這種便利性最大限度地提高了檢測依從性，尤其是在老年人和體弱患者群體中。新冠感染疾病，醫療機構的進入受限，加速了居家檢測的普及，並凸顯了遠距遠距離診斷服務的長期需求。隨著醫療保健系統向預防和個人化醫療轉型，居家體外檢測順應了這些趨勢。透過藥房、網路平台和遠端醫療管道的廣泛應用進一步推動了檢測的普及，使非侵入性篩檢成為體外結直腸癌篩檢需求的主要促進因素。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球體外大腸直腸癌篩檢市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品分類

  • 大便潛血試驗
    • 主要部分
      • 癒創木脂法大便潛血試驗
      • 免疫FOB凝集法
      • 側向流免疫療法 FOB 檢測
      • 免疫球蛋白ELISA檢測
  • 生物標記檢測
    • 主要部分
      • 腫瘤M2-PK糞便檢驗
      • 轉鐵蛋白檢測法
  • 大腸直腸癌DNA篩檢測試
    • 主要部分
      • 甲基化基因檢測
      • 面板DNA檢測

第7章 市場區隔：依影像類型分類

  • 大腸鏡檢查
  • 直腸鏡檢查
  • 電腦斷層掃描
  • 超音波
  • MRI
  • PET掃描

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 診所
  • 診斷檢查室
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Beckman Coulter Inc.（Danaher Corporation）
    • Eiken Chemical Co. Ltd.
    • Epigenomics AG
    • Exact Sciences Corporation
    • Hemosure Inc.
    • Immunostics Inc.（Boditech Med Inc.）
    • Medline Industries LP
    • Merck KGaA
    • Qiagen NV
    • Quest Diagnostics Incorporated
    • R-Biopharm AG
    • Siemens AG
    • Sysmex Corporation
Product Code: SR112026A5383

The global in-vitro colorectal cancer screening tests market size was valued at USD 1,101.3 Million in 2025. The market is projected to reach USD 1,709.7 Million by 2034, exhibiting a CAGR of 4.76% from 2026-2034. North America currently dominates the market, holding a market share of 39.8% in 2025. The market is driven by the rising incidence of colorectal cancer globally, growing awareness about early detection, and increasing adoption of non-invasive diagnostic methods. Technological advancements in test accuracy and ease of use further fuel market growth. Additionally, supportive government initiatives, aging populations, and a shift toward preventive healthcare contribute to increased demand. The convenience, affordability, and efficiency of in-vitro tests compared to traditional screening methods also play a significant role in driving in-vitro colorectal cancer screening tests share .

One major driver in the in-vitro colorectal cancer screening tests market is the growing demand for non-invasive, home-based diagnostic solutions. Traditional methods like colonoscopies are often perceived as uncomfortable, costly, and inconvenient, leading many individuals to avoid screening. In-vitro tests, such as fecal immunochemical tests (FIT) and stool DNA tests, offer a simpler, painless alternative that can be performed at home without clinical assistance. This convenience significantly improves patient compliance and expands screening coverage, especially among aging and at-risk populations. As healthcare systems prioritize preventive care, the shift toward non-invasive testing continues to boost in-vitro colorectal cancer screening tests growth.

The U.S. in-vitro colorectal cancer screening tests market is experiencing steady growth due to strong healthcare infrastructure, rising awareness of early cancer detection, and a shift toward non-invasive, home-based diagnostic options. In 2023, 72.6% of U.S. adults aged 50-75 were up-to-date with colorectal cancer screening, with home-based tests playing a major role in this achievement. Patients increasingly prefer at-home solutions like fecal immunochemical and stool DNA tests over invasive procedures like colonoscopies. Technological advancements, including blood-based screening and biomarker innovations, are further improving test accuracy and expanding available options. Supportive policies, insurance coverage, and a focus on preventive healthcare continue to drive market demand across the U.S. healthcare landscape.

IN-VITRO COLORECTAL CANCER SCREENING TESTS MARKET TRENDS:

Rising Incidence of Colorectal Cancer Globally

One of the main market trends for in-vitro colorectal cancer screening tests is the rising incidence of colorectal cancer worldwide. Around 1.93 million new instances of colorectal cancer and 930,000 related deaths were reported globally in 2020; by 2040, these numbers are predicted to increase by more than 60%. One of the most frequent malignancies to be diagnosed and a major contributor to cancer-related death is colorectal cancer. Contributing factors include sedentary lifestyles, unhealthy diets, rising obesity rates, and aging populations. Early detection significantly improves outcomes, increasing the demand for accessible, non-invasive screening options. In-vitro tests, such as fecal immunochemical and stool Deoxyribonucleic acid (DNA) tests, offer a cost-effective and scalable solution ideal for early-stage detection. Governments and health organizations are increasingly implementing national screening programs to reduce mortality rates. As global awareness grows around the importance of early diagnosis, adoption of in-vitro screening tests continues to strengthen across healthcare systems.

Technological Advancements and Innovation in Screening Methods

Continuing technological advancements have greatly improved the sensitivity, specificity, and convenience of in-vitro screening tests for colorectal cancer. Next-generation fecal immunochemical tests (FIT), DNA stool tests, and biomarker-based diagnostics provide more accurate and stable results compared to older methods. Incorporation of automation, artificial intelligence, and digital pathology into diagnostic processes has decreased turnaround time, decreased human error, and enhanced diagnostic throughput. These enhancements make screening more attractive to patients and healthcare providers alike, leading to higher uptake. Furthermore, the creation of simple home-based test kits enables easy and intimate screening, even particularly attractive to those who are hesitant to submit to invasive exams like colonoscopies. As competition in the diagnostic arena gets fiercer, firms are pouring money into R&D to create innovative, affordable, and scalable in-vitro tests, thus propelling long-term market expansion and shaping early cancer detection strategies.

Growing Preference for Non-Invasive and Home-Based Screening

One of the main forces propelling the in-vitro colon cancer screening tests market outlook is the growing patient demand for non-invasive, at-home diagnostic tools. Conventional methods such as colonoscopy are highly effective but are usually viewed as unpleasant, costly, and inconvenient. On the other hand, in-vitro tests like FIT and multi-target stool DNA tests can be done discreetly at home without bowel preparation, sedation, or hospitalization. This convenience maximizes patient compliance, particularly for elderly and vulnerable patients. In the COVID-19 pandemic era, home-based testing became popular because access to clinical sites was restricted, underlining long-term need for remote diagnostic services. As healthcare systems become more oriented toward prevention and personalized medicine, home-based in-vitro tests fit into these trends. Greater availability through pharmacies, web platforms, and telehealth options further drives adoption, positioning non-invasive screening as a primary driver of in-vitro colorectal cancer screening tests demand.

IN-VITRO COLORECTAL CANCER SCREENING TESTS INDUSTRY SEGMENTATION:

Analysis by Product:

  • Fecal Occult Blood Tests
    • Guaiac FOB Stool Test
    • Immuno-FOB Agglutination Test
    • Lateral Flow Immuno-FOB Test
    • Immuno-FOB ELISA Test
  • Biomarker Tests
    • Tumor M2-PK Stool Test
    • Transferrin Assays
  • CRC DNA Screening Tests
    • Methylated Gene Testing
    • Panel DNA Tests

Based on the in-vitro colorectal cancer screening tests forecast, the fecal occult blood tests (FOBTs) account for the majority of shares in the in-vitro colorectal cancer screening tests market due to their affordability, ease of use, and widespread availability. These tests are non-invasive, require no specialized equipment, and can be performed at home, making them highly accessible and widely accepted, especially in large-scale public health screening programs. Their low cost compared to other diagnostic methods makes them particularly suitable for use in resource-limited settings and for population-wide screening initiatives. Additionally, FOBTs have long been integrated into clinical guidelines, which supports consistent demand. While newer technologies are emerging, the simplicity, cost-effectiveness, and established clinical utility of fecal occult blood tests continue to drive their dominant market share globally.

Analysis by Imaging Type:

  • Colonoscopy
  • Proctoscopy
  • CT Scan
  • Ultrasound
  • MRI
  • PET Scan

Colonoscopy dominates the market demand in colorectal cancer screening due to its status as the gold standard for both detection and prevention. Unlike in-vitro tests, colonoscopy allows direct visualization of the entire colon and enables the removal of precancerous polyps during the same procedure, reducing cancer risk. Its high sensitivity and diagnostic accuracy make it the preferred choice among healthcare professionals for high-risk individuals or those with positive in-vitro test results. Additionally, colonoscopy is often recommended in national screening guidelines and widely covered by insurance, further encouraging its use. Despite being invasive and requiring preparation, its ability to provide immediate, actionable results and long-term screening intervals makes it a trusted and effective option in colorectal cancer prevention and early diagnosis.

Analysis by End User:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Others

According to the in-vitro colorectal cancer screening tests analysis, the diagnostic laboratories represent the majority of shares in the in-vitro colorectal cancer screening tests market owing to their established infrastructure, advanced testing capabilities, and ability to process large volumes of samples with high accuracy. These laboratories offer a wide range of specialized tests, including fecal immunochemical tests (FIT), stool DNA tests, and biomarker-based assays, enabling comprehensive and early detection of colorectal cancer. Their integration with healthcare providers and insurance networks ensures broader patient access and coverage, enhancing test adoption. Additionally, diagnostic labs continuously invest in automation, quality control, and innovation to improve turnaround times and diagnostic reliability. Their nationwide reach, regulatory compliance, and participation in public screening programs position them as key players driving efficiency, accessibility, and trust in colorectal cancer screening services.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America is the leading region in the in-vitro colorectal cancer screening tests market due to a combination of advanced healthcare infrastructure, high public awareness, and strong government support for cancer screening programs. The region benefits from early adoption of innovative technologies, including non-invasive tests like fecal immunochemical, stool DNA, and emerging blood-based assays. Favorable reimbursement policies and widespread health insurance coverage further promote regular screening among high-risk populations. Public health campaigns and national screening guidelines encourage early detection, improving patient outcomes and driving market demand. Additionally, the presence of key industry players and continuous investment in research and development contribute to a competitive and innovation-driven environment. These factors collectively position North America as the dominant force in this growing market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES IN-VITRO COLORECTAL CANCER SCREENING MARKET ANALYSIS

The United States in-vitro colorectal cancer screening market is primarily driven by the rising incidence and prevalence of colorectal cancer, which is driving increased demand for early detection tools. According to the American Cancer Society, colorectal cancer is the third most common cause of cancer-related deaths in men and the fourth most common in women in the United States. In 2025, colorectal cancer is projected to cause approximately 52,900 deaths. Lifestyle trends such as obesity, sedentary behavior, smoking, alcohol consumption, and diets high in red and processed meats are contributing to rising colorectal cancer risks, prompting more widespread screening. According to the U.S. Centers for Disease Control and Prevention (CDC), obesity prevalence among adults in the United States reached 40.3% from August 2021 to August 2023. Other than this, advancements in automation, AI-enhanced laboratory platforms, and next-generation sequencing have increased throughput and lowered per-test costs, making sophisticated assays more accessible. A heightened emphasis on early detection through value-based care models is also strengthening insurer and Medicare reimbursement for non-invasive diagnostics, thereby broadening patient access. Government-funded cancer prevention programs and enhanced regulatory support for novel test approvals are reducing barriers and catalyzing market growth as labs and providers increasingly integrate these in-vitro solutions into routine screening protocols.

ASIA PACIFIC IN-VITRO COLORECTAL CANCER SCREENING MARKET ANALYSIS

The Asia Pacific in-vitro colorectal cancer screening market is expanding due to advancements in molecular diagnostics and biomarker research, enabling the development of more precise and sensitive screening assays. For instance, the molecular diagnostics market in India reached USD 1.3 Million in 2024 and is forecasted to grow at a CAGR of 7.7% from 2025-2033, as per industry reports. Rising demand for early cancer detection in increasing geriatric populations across countries such as Japan, South Korea, and Australia is also expediting the shift toward laboratory-based preventive diagnostics. In 2023, individuals aged 65 years and over accounted for 30% of the total population of Japan. Increasing prevalence of colorectal cancer among younger age groups is also prompting healthcare authorities to lower the recommended screening age, expanding the target demographic for in-vitro testing. The growing presence of international diagnostic companies is fostering technology transfer and innovation within local markets.

EUROPE IN-VITRO COLORECTAL CANCER SCREENING MARKET ANALYSIS

The growth of the Europe in-vitro colorectal cancer screening market is largely fueled by the emergence of novel biomarker assays, which is driving demand for more sensitive, non-invasive lab tests that offer improved diagnostic accuracy and patient comfort. Moreover, increased public funding for cancer registries and large-scale epidemiological studies is enabling data-driven, risk-based screening strategies tailored to subpopulations, boosting uptake of in-vitro diagnostics. Increasing telehealth integration across the region is also transforming sample tracking and lab coordination, reducing turnaround times and enhancing patient compliance. Additionally, national screening programs are increasingly integrating in-vitro testing into routine preventive care, supported by eHealth solutions that streamline patient tracking and follow-up. According to the European Commission, the average overall composite score for the EU increased from 72% to 79% in 2023 on the eHealth indicator, highlighting a robust eHealth maturity rate for the region. Other than this, heightened focus on sustainability in healthcare has led to greater interest in minimally invasive, low-waste diagnostic solutions, with in-vitro tests offering a lower environmental footprint compared to traditional procedures.

LATIN AMERICA IN-VITRO COLORECTAL CANCER SCREENING MARKET ANALYSIS

The Latin America in-vitro colorectal cancer screening market is experiencing robust growth due to the increasing prevalence of colorectal cancer, which is driving the demand for effective screening methods. For instance, 60,118 cases of colorectal cancer were recorded in Brazil in 2022, as per a report by the World Cancer Research Fund. Of these, men accounted for 30,164 cases, while women accounted for 29,954 cases. In response, several countries in the region are implementing national screening programs that utilize non-invasive in-vitro tests to improve early detection and reduce mortality rates associated with colorectal cancer. Besides this, advancements in diagnostic technologies have led to the development of more accurate and cost-effective in-vitro screening tests, making them accessible to a broader population and supporting market growth.

MIDDLE EAST AND AFRICA IN-VITRO COLORECTAL CANCER SCREENING MARKET ANALYSIS

The Middle East and Africa in-vitro colorectal cancer screening market is significantly driven by increasing investments in healthcare infrastructure modernization and the expansion of diagnostic laboratories. Rising government focus on implementing nationwide cancer screening policies is improving early detection efforts. Besides this, private sector growth and partnerships with global diagnostic companies are enhancing the availability and affordability of advanced in-vitro screening technologies. As reported, Saudi Arabia is actively pursuing privatization in its healthcare sector, aiming to increase private sector contribution from 40% to 65% by 2030. Initiatives to train healthcare professionals on the latest diagnostic methods are also helping increase screening rates across the region.

COMPETITIVE LANDSCAPE:

Competition is driven by innovation, technology, and an emphasis on non-invasive diagnostic tests. Several players compete through the creation of more precise, easy-to-use, and affordable tests, such as stool-based DNA, fecal immunochemical, and blood-based tests. The market witnesses steady investment in research and development to improve test sensitivity and broaden accessibility, particularly through home-based solutions. Strategic partnerships, regulatory clearances, and increased insurance coverage are some of the drivers of competition. Firms are also placing a focus on digital health integration and patient outreach to drive screening compliance. As the need for early detection increases, the market is lively, with high stakes being played to gain share through best-in-class clinical performance and extensive market reach.

The report provides a comprehensive analysis of the competitive landscape in the in-vitro colorectal cancer screening tests market with detailed profiles of all major companies, including:

  • Beckman Coulter Inc. (Danaher Corporation)
  • Eiken Chemical Co. Ltd.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Hemosure Inc.
  • Immunostics Inc. (Boditech Med Inc.)
  • Medline Industries LP
  • Merck KGaA
  • Qiagen N.V.
  • Quest Diagnostics Incorporated
  • R-Biopharm AG
  • Siemens AG
  • Sysmex Corporation

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the in-vitro colorectal cancer screening tests market?

2. What is the future outlook of in-vitro colorectal cancer screening tests market?

3. What are the key factors driving the in-vitro colorectal cancer screening tests market?

4. Which region accounts for the largest in-vitro colorectal cancer screening tests market share?

5. Which are the leading companies in the global in-vitro colorectal cancer screening tests market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global In-vitro Colorectal Cancer Screening Tests Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Fecal Occult Blood Tests
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Guaiac FOB Stool Test
      • 6.1.2.2 Immuno-FOB Agglutination Test
      • 6.1.2.3 Lateral Flow Immuno-FOB Test
      • 6.1.2.4 Immuno-FOB ELISA Test
    • 6.1.3 Market Forecast
  • 6.2 Biomarker Tests
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Tumor M2-PK Stool Test
      • 6.2.2.2 Transferrin Assays
    • 6.2.3 Market Forecast
  • 6.3 CRC DNA Screening Tests
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Methylated Gene Testing
      • 6.3.2.2 Panel DNA Tests
    • 6.3.3 Market Forecast

7 Market Breakup by Imaging Type

  • 7.1 Colonoscopy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Proctoscopy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 CT Scan
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Ultrasound
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 MRI
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 PET Scan
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Diagnostic Laboratories
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Beckman Coulter Inc. (Danaher Corporation)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Eiken Chemical Co. Ltd.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 Epigenomics AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Exact Sciences Corporation
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Hemosure Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Immunostics Inc. (Boditech Med Inc.)
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Medline Industries LP
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 SWOT Analysis
    • 14.3.8 Merck KGaA
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Qiagen N.V.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Quest Diagnostics Incorporated
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 R-Biopharm AG
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Siemens AG
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Sysmex Corporation
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: In-vitro Colorectal Cancer Screening Tests Market: Major Drivers and Challenges
  • Figure 2: Global: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: In-vitro Colorectal Cancer Screening Tests Market: Breakup by Product (in %), 2025
  • Figure 5: Global: In-vitro Colorectal Cancer Screening Tests Market: Breakup by Imaging Type (in %), 2025
  • Figure 6: Global: In-vitro Colorectal Cancer Screening Tests Market: Breakup by End User (in %), 2025
  • Figure 7: Global: In-vitro Colorectal Cancer Screening Tests Market: Breakup by Region (in %), 2025
  • Figure 8: Global: In-vitro Colorectal Cancer Screening Tests (Fecal Occult Blood Tests) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: In-vitro Colorectal Cancer Screening Tests (Fecal Occult Blood Tests) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: In-vitro Colorectal Cancer Screening Tests (Biomarker Tests) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: In-vitro Colorectal Cancer Screening Tests (Biomarker Tests) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: In-vitro Colorectal Cancer Screening Tests (CRC DNA Screening Tests) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: In-vitro Colorectal Cancer Screening Tests (CRC DNA Screening Tests) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: In-vitro Colorectal Cancer Screening Tests (Colonoscopy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: In-vitro Colorectal Cancer Screening Tests (Colonoscopy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: In-vitro Colorectal Cancer Screening Tests (Proctoscopy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: In-vitro Colorectal Cancer Screening Tests (Proctoscopy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: In-vitro Colorectal Cancer Screening Tests (CT Scan) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: In-vitro Colorectal Cancer Screening Tests (CT Scan) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: In-vitro Colorectal Cancer Screening Tests (Ultrasound) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: In-vitro Colorectal Cancer Screening Tests (Ultrasound) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: In-vitro Colorectal Cancer Screening Tests (MRI) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: In-vitro Colorectal Cancer Screening Tests (MRI) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: In-vitro Colorectal Cancer Screening Tests (PET Scan) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: In-vitro Colorectal Cancer Screening Tests (PET Scan) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: In-vitro Colorectal Cancer Screening Tests (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: In-vitro Colorectal Cancer Screening Tests (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: In-vitro Colorectal Cancer Screening Tests (Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: In-vitro Colorectal Cancer Screening Tests (Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: In-vitro Colorectal Cancer Screening Tests (Diagnostic Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: In-vitro Colorectal Cancer Screening Tests (Diagnostic Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: In-vitro Colorectal Cancer Screening Tests (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: In-vitro Colorectal Cancer Screening Tests (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: North America: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: North America: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: United States: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: United States: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Canada: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Canada: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Asia-Pacific: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Asia-Pacific: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: China: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: China: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Japan: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Japan: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: India: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: India: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: South Korea: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: South Korea: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Australia: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Australia: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Indonesia: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Indonesia: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Others: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Others: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Europe: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Europe: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Germany: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Germany: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: France: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: France: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: United Kingdom: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: United Kingdom: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Italy: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Italy: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Spain: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Spain: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Russia: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Russia: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Others: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Others: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Latin America: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Latin America: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Brazil: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Brazil: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Mexico: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Mexico: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Others: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Others: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Middle East and Africa: In-vitro Colorectal Cancer Screening Tests Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Middle East and Africa: In-vitro Colorectal Cancer Screening Tests Market: Breakup by Country (in %), 2025
  • Figure 82: Middle East and Africa: In-vitro Colorectal Cancer Screening Tests Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Global: In-vitro Colorectal Cancer Screening Tests Industry: SWOT Analysis
  • Figure 84: Global: In-vitro Colorectal Cancer Screening Tests Industry: Value Chain Analysis
  • Figure 85: Global: In-vitro Colorectal Cancer Screening Tests Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: In-vitro Colorectal Cancer Screening Tests Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: In-vitro Colorectal Cancer Screening Tests Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 3: Global: In-vitro Colorectal Cancer Screening Tests Market Forecast: Breakup by Imaging Type (in Million USD), 2026-2034
  • Table 4: Global: In-vitro Colorectal Cancer Screening Tests Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: In-vitro Colorectal Cancer Screening Tests Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: In-vitro Colorectal Cancer Screening Tests Market: Competitive Structure
  • Table 7: Global: In-vitro Colorectal Cancer Screening Tests Market: Key Players